Enhancing the effectiveness of human cardiac stem cell therapy

增强人类心脏干细胞治疗的有效性

基本信息

  • 批准号:
    8845247
  • 负责人:
  • 金额:
    $ 38.91万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2012
  • 资助国家:
    美国
  • 起止时间:
    2012-07-16 至 2017-05-31
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): Ischemic heart disease remains as the single largest cause of mortality in the United States. Delivery of c-kit positive human cardiac stem cells (hCSCs) is a very promising therapeutic approach in repairing the infarcted heart, but is severely limited by the poor survival of donor cells. Carbon monoxide (CO), a byproduct of heme oxygenase 1 (HO-1), has a potent anti- apoptotic, cytoprotective effect against ischemia/reperfusion injury to cardiomyocytes. However, it is not known whether HO-1/CO is cytoprotective for hCSCs. Our pilot studies found that HO-1/CO plays an important role in mediating hCSC survival ability. Therefore, this application focuses on testing our hypothesis that HO-1/CO promotes human cardiac stem cell survival vial the activation of survival signal pathways and the cytokine effects, as well as enhances the stem cell therapy efficacy and heart function after transplantation into immunodeficient mouse heart following myocardial infarction. Thus, we will examine whether hCSCs pretreated with an HO-1 inducer (CoPP), or a CO releasing molecule (CORM-3), will exhibit greater abilities in cell survival, proliferation, migration, endothelial and cardiomyogenic differentiation (Aim 1), and understand the molecular mechanisms that underlie the effect of HO-1/CO on hCSC survival signal pathways, resistance to apoptosis, ROS generation and cytokine release (Aim 2). Aim 3 of this proposal will test whether transplantation of the preconditioned eGFP+-hCSCs will result in improvement in invivo hCSC survival and homing, endogenous mouse CSC proliferation and differentiation, and cardiac structure and function with immunodeficient mouse (SCID) model following myocardial infarction. Knowledge gained from the above experiments will provide the essential implications on the strategies to enhance hCSC survival after transplantation and, therefore, their efficacy in clinical repairing infarcted myocardium for the cell therapy of patients with ischemic heart disease.
描述(由申请人提供):缺血性心脏病仍然是美国最大的单一死亡原因。递送c-kit阳性的人心脏干细胞(hCSCs)是修复梗死心脏的非常有前途的治疗方法,但严重受限于供体细胞的存活率差。一氧化碳(CO)是血红素加氧酶1(HO-1)的副产物,对心肌细胞缺血/再灌注损伤具有抗凋亡、细胞保护作用。然而,尚不清楚HO-1/CO是否对hCSC具有细胞保护作用。我们的初步研究发现HO-1/CO在介导hCSC存活能力中起重要作用。因此,本申请的重点是验证我们的假设,即HO-1/CO通过激活存活信号通路和细胞因子效应促进人心脏干细胞存活,以及移植到免疫缺陷小鼠心肌梗死后的干细胞治疗效果和心脏功能。因此,我们将研究用HO-1诱导剂(CoPP)或CO释放分子(CORM-3)预处理的hCSC是否会在细胞存活、增殖、迁移、内皮和心肌分化(Aim 1)方面表现出更强的能力,并了解HO-1/CO对hCSC存活信号通路、抗凋亡、ROS生成和细胞因子释放(目的2)。该提议的目的3将测试预处理的eGFP+-hCSC的移植是否会导致心肌梗死后免疫缺陷小鼠(SCID)模型的体内hCSC存活和归巢、内源性小鼠CSC增殖和分化以及心脏结构和功能的改善。从上述实验中获得的知识将为移植后提高hCSC存活率的策略提供重要的启示,因此,它们在缺血性心脏病患者的细胞治疗中修复梗死心肌的临床功效。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Chuanxi Cai其他文献

Chuanxi Cai的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Chuanxi Cai', 18)}}的其他基金

Protein therapy to treat virus induced cardiopulmonary injury
蛋白质疗法治疗病毒引起的心肺损伤
  • 批准号:
    10636817
  • 财政年份:
    2022
  • 资助金额:
    $ 38.91万
  • 项目类别:
Protein therapy to treat virus induced cardiopulmonary injury
蛋白质疗法治疗病毒引起的心肺损伤
  • 批准号:
    10747665
  • 财政年份:
    2022
  • 资助金额:
    $ 38.91万
  • 项目类别:
Enhancing the effectiveness of human cardiac stem cell therapy
增强人类心脏干细胞治疗的有效性
  • 批准号:
    9772670
  • 财政年份:
    2018
  • 资助金额:
    $ 38.91万
  • 项目类别:
Enhancing the effectiveness of human cardiac stem cell therapy
增强人类心脏干细胞治疗的有效性
  • 批准号:
    8669819
  • 财政年份:
    2012
  • 资助金额:
    $ 38.91万
  • 项目类别:
Enhancing the effectiveness of human cardiac stem cell therapy
增强人类心脏干细胞治疗的有效性
  • 批准号:
    8343314
  • 财政年份:
    2012
  • 资助金额:
    $ 38.91万
  • 项目类别:
Enhancing the effectiveness of human cardiac stem cell therapy
增强人类心脏干细胞治疗的有效性
  • 批准号:
    8773643
  • 财政年份:
    2012
  • 资助金额:
    $ 38.91万
  • 项目类别:
Enhancing the effectiveness of human cardiac stem cell therapy
增强人类心脏干细胞治疗的有效性
  • 批准号:
    8511813
  • 财政年份:
    2012
  • 资助金额:
    $ 38.91万
  • 项目类别:
MG53 mediated myocardial repair for ischemic heart disease
MG53介导缺血性心脏病的心肌修复
  • 批准号:
    7962760
  • 财政年份:
    2010
  • 资助金额:
    $ 38.91万
  • 项目类别:
MESENCHYMAL STEM CELL THERAPY FOR INFARCT PROJ 3 2009
间充质干细胞治疗梗死项目 3 2009
  • 批准号:
    8168213
  • 财政年份:
    2010
  • 资助金额:
    $ 38.91万
  • 项目类别:
MG53 mediated myocardial repair for ischemic heart disease
MG53介导缺血性心脏病的心肌修复
  • 批准号:
    8092773
  • 财政年份:
    2010
  • 资助金额:
    $ 38.91万
  • 项目类别:

相似海外基金

University of Aberdeen and Vertebrate Antibodies Limited KTP 23_24 R1
阿伯丁大学和脊椎动物抗体有限公司 KTP 23_24 R1
  • 批准号:
    10073243
  • 财政年份:
    2024
  • 资助金额:
    $ 38.91万
  • 项目类别:
    Knowledge Transfer Partnership
Role of Natural Antibodies and B1 cells in Fibroproliferative Lung Disease
天然抗体和 B1 细胞在纤维增生性肺病中的作用
  • 批准号:
    10752129
  • 财政年份:
    2024
  • 资助金额:
    $ 38.91万
  • 项目类别:
CAREER: Next-generation protease inhibitor discovery with chemically diversified antibodies
职业:利用化学多样化的抗体发现下一代蛋白酶抑制剂
  • 批准号:
    2339201
  • 财政年份:
    2024
  • 资助金额:
    $ 38.91万
  • 项目类别:
    Continuing Grant
Isolation and characterisation of monoclonal antibodies for the treatment or prevention of antibiotic resistant Acinetobacter baumannii infections
用于治疗或预防抗生素耐药鲍曼不动杆菌感染的单克隆抗体的分离和表征
  • 批准号:
    MR/Y008693/1
  • 财政年份:
    2024
  • 资助金额:
    $ 38.91万
  • 项目类别:
    Research Grant
Discovery of novel nodal antibodies in the central nervous system demyelinating diseases and elucidation of the mechanisms through an optic nerve demyelination model
发现中枢神经系统脱髓鞘疾病中的新型节点抗体并通过视神经脱髓鞘模型阐明其机制
  • 批准号:
    23K14783
  • 财政年份:
    2023
  • 资助金额:
    $ 38.91万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Elucidation of the mechanisms controlling the physicochemical properties and functions of supercharged antibodies and development of their applications
阐明控制超电荷抗体的理化性质和功能的机制及其应用开发
  • 批准号:
    23KJ0394
  • 财政年份:
    2023
  • 资助金额:
    $ 38.91万
  • 项目类别:
    Grant-in-Aid for JSPS Fellows
Developing first-in-class aggregation-specific antibodies for a severe genetic neurological disease
开发针对严重遗传神经系统疾病的一流聚集特异性抗体
  • 批准号:
    10076445
  • 财政年份:
    2023
  • 资助金额:
    $ 38.91万
  • 项目类别:
    Grant for R&D
PLA2G2D Antibodies for Cancer Immunotherapy
用于癌症免疫治疗的 PLA2G2D 抗体
  • 批准号:
    10699504
  • 财政年份:
    2023
  • 资助金额:
    $ 38.91万
  • 项目类别:
Genetic adjuvants to elicit neutralizing antibodies against HIV
基因佐剂可引发抗艾滋病毒中和抗体
  • 批准号:
    10491642
  • 财政年份:
    2023
  • 资助金额:
    $ 38.91万
  • 项目类别:
Novel Immunogens to Elicit Broadly Cross-reactive Antibodies That Target the Hemagglutinin Head Trimer Interface
新型免疫原可引发针对血凝素头三聚体界面的广泛交叉反应抗体
  • 批准号:
    10782567
  • 财政年份:
    2023
  • 资助金额:
    $ 38.91万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了